Syndecan-1 expression

a novel prognostic marker in pancreatic cancer

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

Objectives: Loss of epithelial heparan sulfate proteoglycan syndecan-1 has been associated with a more aggressive behavior in various cancer forms, but the prognostic significance of syndecan-1 expression in colorectal cancer is unclear. The aim of this study was to evaluate the prognostic value of immunohistochemical syndecan-1 expression in a series of 237 patients with colorectal cancer. Methods: Paraffin-em bedded formalin-fixed specimens were stained with a syndecan-1-specific monoclonal antibody, and both the epithelial and stromal expression were analyzed. Results: Epithelial expression of syndecan-1 was seen in 222 tumors (94%), and it was associated with low stage of disease (p = 0.002) and low histological differentiation grade (p = 0.048). The cumulative 5-year survival of patients with weak and strong syndecan-1 expression was 49 and 54%, respectively (p = 0.234). Syndecan-1 stromal immunoreactivity was observed in 138 tumors (58%), but lacked prognostic significance. Staining pattern and distribution can be viewed from digitized representative microscope slides (virtual slides) at http://www.webmicroscope.net/supplements/syndecan. Conclusions:The results are in line with previous reports in that low epithelial syndecan-1 expression was associated with a higher histological grade and a more advanced clinical stage of the patients. This study shows that syndecan-1 is expressed also in stromal tissue of colorectal cancer, but it does not support the proposed role of stromal syndecan-1 expression as a marker of poor clinical outcome. Copyright (C) 2005 S. Karger AG, Basel.
Alkuperäiskielienglanti
LehtiOncology
Vuosikerta68
Numero2/3
Sivut97-106
Sivumäärä10
ISSN0030-2414
DOI - pysyväislinkit
TilaJulkaistu - 2005
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Lainaa tätä

@article{ff46d0fe7dc8459dbe8f58007a98d432,
title = "Syndecan-1 expression: a novel prognostic marker in pancreatic cancer",
abstract = "Objectives: Loss of epithelial heparan sulfate proteoglycan syndecan-1 has been associated with a more aggressive behavior in various cancer forms, but the prognostic significance of syndecan-1 expression in colorectal cancer is unclear. The aim of this study was to evaluate the prognostic value of immunohistochemical syndecan-1 expression in a series of 237 patients with colorectal cancer. Methods: Paraffin-em bedded formalin-fixed specimens were stained with a syndecan-1-specific monoclonal antibody, and both the epithelial and stromal expression were analyzed. Results: Epithelial expression of syndecan-1 was seen in 222 tumors (94{\%}), and it was associated with low stage of disease (p = 0.002) and low histological differentiation grade (p = 0.048). The cumulative 5-year survival of patients with weak and strong syndecan-1 expression was 49 and 54{\%}, respectively (p = 0.234). Syndecan-1 stromal immunoreactivity was observed in 138 tumors (58{\%}), but lacked prognostic significance. Staining pattern and distribution can be viewed from digitized representative microscope slides (virtual slides) at http://www.webmicroscope.net/supplements/syndecan. Conclusions:The results are in line with previous reports in that low epithelial syndecan-1 expression was associated with a higher histological grade and a more advanced clinical stage of the patients. This study shows that syndecan-1 is expressed also in stromal tissue of colorectal cancer, but it does not support the proposed role of stromal syndecan-1 expression as a marker of poor clinical outcome. Copyright (C) 2005 S. Karger AG, Basel.",
keywords = "syndecan-1, pancreatic cancer, pancreatitis, prognosis, survival, immunohistochemistry, CELL-SURFACE PROTEOGLYCAN, HEPARAN-SULFATE PROTEOGLYCANS, MAMMARY EPITHELIAL-CELLS, EMBRYONIC TOOTH MESENCHYME, FINE-STRUCTURE, CARCINOMA, MATRIX, DIFFERENTIATION, ASSOCIATION, TENASCIN",
author = "A Juuti and S Nordling and J Lundin and J Louhimo and C Haglund",
year = "2005",
doi = "10.1159/000085702",
language = "English",
volume = "68",
pages = "97--106",
journal = "Oncology",
issn = "0030-2414",
publisher = "Karger",
number = "2/3",

}

Syndecan-1 expression : a novel prognostic marker in pancreatic cancer. / Juuti, A ; Nordling, S ; Lundin, J ; Louhimo, J ; Haglund, C .

julkaisussa: Oncology, Vuosikerta 68, Nro 2/3, 2005, s. 97-106.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Syndecan-1 expression

T2 - a novel prognostic marker in pancreatic cancer

AU - Juuti, A

AU - Nordling, S

AU - Lundin, J

AU - Louhimo, J

AU - Haglund, C

PY - 2005

Y1 - 2005

N2 - Objectives: Loss of epithelial heparan sulfate proteoglycan syndecan-1 has been associated with a more aggressive behavior in various cancer forms, but the prognostic significance of syndecan-1 expression in colorectal cancer is unclear. The aim of this study was to evaluate the prognostic value of immunohistochemical syndecan-1 expression in a series of 237 patients with colorectal cancer. Methods: Paraffin-em bedded formalin-fixed specimens were stained with a syndecan-1-specific monoclonal antibody, and both the epithelial and stromal expression were analyzed. Results: Epithelial expression of syndecan-1 was seen in 222 tumors (94%), and it was associated with low stage of disease (p = 0.002) and low histological differentiation grade (p = 0.048). The cumulative 5-year survival of patients with weak and strong syndecan-1 expression was 49 and 54%, respectively (p = 0.234). Syndecan-1 stromal immunoreactivity was observed in 138 tumors (58%), but lacked prognostic significance. Staining pattern and distribution can be viewed from digitized representative microscope slides (virtual slides) at http://www.webmicroscope.net/supplements/syndecan. Conclusions:The results are in line with previous reports in that low epithelial syndecan-1 expression was associated with a higher histological grade and a more advanced clinical stage of the patients. This study shows that syndecan-1 is expressed also in stromal tissue of colorectal cancer, but it does not support the proposed role of stromal syndecan-1 expression as a marker of poor clinical outcome. Copyright (C) 2005 S. Karger AG, Basel.

AB - Objectives: Loss of epithelial heparan sulfate proteoglycan syndecan-1 has been associated with a more aggressive behavior in various cancer forms, but the prognostic significance of syndecan-1 expression in colorectal cancer is unclear. The aim of this study was to evaluate the prognostic value of immunohistochemical syndecan-1 expression in a series of 237 patients with colorectal cancer. Methods: Paraffin-em bedded formalin-fixed specimens were stained with a syndecan-1-specific monoclonal antibody, and both the epithelial and stromal expression were analyzed. Results: Epithelial expression of syndecan-1 was seen in 222 tumors (94%), and it was associated with low stage of disease (p = 0.002) and low histological differentiation grade (p = 0.048). The cumulative 5-year survival of patients with weak and strong syndecan-1 expression was 49 and 54%, respectively (p = 0.234). Syndecan-1 stromal immunoreactivity was observed in 138 tumors (58%), but lacked prognostic significance. Staining pattern and distribution can be viewed from digitized representative microscope slides (virtual slides) at http://www.webmicroscope.net/supplements/syndecan. Conclusions:The results are in line with previous reports in that low epithelial syndecan-1 expression was associated with a higher histological grade and a more advanced clinical stage of the patients. This study shows that syndecan-1 is expressed also in stromal tissue of colorectal cancer, but it does not support the proposed role of stromal syndecan-1 expression as a marker of poor clinical outcome. Copyright (C) 2005 S. Karger AG, Basel.

KW - syndecan-1

KW - pancreatic cancer

KW - pancreatitis

KW - prognosis

KW - survival

KW - immunohistochemistry

KW - CELL-SURFACE PROTEOGLYCAN

KW - HEPARAN-SULFATE PROTEOGLYCANS

KW - MAMMARY EPITHELIAL-CELLS

KW - EMBRYONIC TOOTH MESENCHYME

KW - FINE-STRUCTURE

KW - CARCINOMA

KW - MATRIX

KW - DIFFERENTIATION

KW - ASSOCIATION

KW - TENASCIN

U2 - 10.1159/000085702

DO - 10.1159/000085702

M3 - Article

VL - 68

SP - 97

EP - 106

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2/3

ER -